Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST101 (Ledaceibup) in Chinese patients with hypercholesterolemia
ChiCTR2400089193Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and familial hypercholesterolemia (FH) comparing HST101 with Placebo (2 arms). Primary endpoints: Percent change from baseline in LDL-C level at week 12 (Friedewald formula) and Percent change from baseline in mean LDL-C levels at weeks 10 and 12 (Friedewald formula). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on ChiCTR2400089193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089193.